Literature DB >> 18057229

A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells.

Rosario Machado-Pinilla1, Isabel Sánchez-Pérez, José Ramón Murguía, Leandro Sastre, Rosario Perona.   

Abstract

Dyskerin gene is mutated in patients with X-linked dyskeratosis congenita (X-DC), which results in greatly reduced levels of telomerase activity. A genetic suppressor element (GSE) termed GSE24-2 has been isolated in a screening for cisplatin resistance. GSE24-2-expressing cells presented impaired telomerase inhibition following in vitro exposure to chemotherapies, such as cisplatin, or telomerase inhibitors. The promoter of the telomerase component hTERT was constitutively activated in GSE24-2 cells in a c-myc expression-dependent manner. Deletion analyses and mutagenesis of the human c-myc promoter demonstrated that the target sequence for activation was the nuclease hypersensitive element-III (NHEIII) site located upstream to the P1 region of the promoter. Further, expression of GSE24-2 in cell lines derived from patients with X-DC and in VA13 cells induced increased hTERT RNA and hTR levels and recovery of telomerase activity. Finally, expression of GSE24-2 was able to rescue X-DC fibroblasts from premature senescence. These data demonstrate that this domain of dyskerin plays an important role in telomerase maintenance following cell insults such as cisplatin treatment, and in telomerase-defective cells in patients with X-DC. The expression of this dyskerin fragment has a dominant function in X-DC cells and could provide the basis for a therapeutic approach to this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057229     DOI: 10.1182/blood-2007-04-083261

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells.

Authors:  Laura Pintado-Berninches; Beatriz Fernandez-Varas; Carlos Benitez-Buelga; Cristina Manguan-Garcia; Almudena Serrano-Benitez; Laura Iarriccio; Jaime Carrillo; Guillermo Guenechea; Susana P Egusquiaguirre; Jose-Luis Pedraz; Rosa M Hernández; Manoli Igartua; Elena G Arias-Salgado; Felipe Cortés-Ledesma; Leandro Sastre; Rosario Perona
Journal:  Cell Death Differ       Date:  2019-01-22       Impact factor: 15.828

Review 2.  Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.

Authors:  Sze Yuen Lew; Michael Weng Lok Phang; Pit Shan Chong; Jaydeep Roy; Chi Him Poon; Wing Shan Yu; Lee Wei Lim; Kah Hui Wong
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-19

3.  p53 pathway activation by telomere attrition in X-DC primary fibroblasts occurs in the absence of ribosome biogenesis failure and as a consequence of DNA damage.

Authors:  J Carrillo; A González; C Manguán-García; L Pintado-Berninches; R Perona
Journal:  Clin Transl Oncol       Date:  2013-09-25       Impact factor: 3.405

4.  Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain.

Authors:  Rosario Machado-Pinilla; Jaime Carrillo; Cristina Manguan-Garcia; Leandro Sastre; Alexander Mentzer; B-W Gu; Philip J Mason; Rosario Perona
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

Review 5.  Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder.

Authors:  Galina Glousker; Fabien Touzot; Patrick Revy; Yehuda Tzfati; Sharon A Savage
Journal:  Br J Haematol       Date:  2015-05-04       Impact factor: 6.998

6.  Expression of the genetic suppressor element 24.2 (GSE24.2) decreases DNA damage and oxidative stress in X-linked dyskeratosis congenita cells.

Authors:  Cristina Manguan-Garcia; Laura Pintado-Berninches; Jaime Carrillo; Rosario Machado-Pinilla; Leandro Sastre; Carme Pérez-Quilis; Isabel Esmoris; Amparo Gimeno; Jose Luis García-Giménez; Federico V Pallardó; Rosario Perona
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 7.  The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.

Authors:  Paz Nombela; Borja Miguel-López; Sandra Blanco
Journal:  Mol Cancer       Date:  2021-01-18       Impact factor: 27.401

8.  Generation of dyskeratosis congenita-like hematopoietic stem cells through the stable inhibition of DKC1.

Authors:  Rosario Perona; Guillermo Guenechea; Carlos Carrascoso-Rubio; Hidde A Zittersteijn; Laura Pintado-Berninches; Beatriz Fernández-Varas; M Luz Lozano; Cristina Manguan-Garcia; Leandro Sastre; Juan A Bueren
Journal:  Stem Cell Res Ther       Date:  2021-01-29       Impact factor: 6.832

9.  GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dyskerin Mutant Cells.

Authors:  Laura Iarriccio; Cristina Manguán-García; Laura Pintado-Berninches; José Miguel Mancheño; Antonio Molina; Rosario Perona; Leandro Sastre
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 10.  Multisystemic Manifestations in Rare Diseases: The Experience of Dyskeratosis Congenita.

Authors:  Michele Callea; Diego Martinelli; Francisco Cammarata-Scalisi; Chiara Grimaldi; Houweyda Jilani; Piercesare Grimaldi; Colin Eric Willoughby; Antonino Morabito
Journal:  Genes (Basel)       Date:  2022-03-11       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.